Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation

Area of Science:

• Immunology
• Molecular Biology
• Cell Signaling

Background:

• Mitogen-activated protein kinase (MAPK) pathway, specifically ERK, is vital in cellular processes.
• MEK1 and MEK2 are the sole activators of ERK, making them key targets for cancer and autoimmune disease therapies.
• The precise role of MEK signaling in immune cell activation remains incompletely understood.

Purpose of the Study:

• To elucidate how MEK1 and MEK2 signaling pathways regulate immune cell activation.
• To investigate the distinct roles of MEK1 and MEK2 isoforms in lymphocyte function and disease pathogenesis.

Main Methods:

• Generation of specific Mek1 deletions in hematopoietic cells within a Mek2 null background.
• Analysis of an allelic series of Mek mutants to assess MEK protein levels and ERK activation.
• Phenotypic characterization of mutant mice, including lifespan, immune cell activation, and disease development.

Main Results:

• Distinct levels of spontaneous B cell activation were observed, inversely correlated with MEK protein and ERK activation levels.
• Mek1 and Mek2 null mutants exhibited normal lifespans.
• Mutants with a single functional Mek1 or Mek2 allele in hematopoietic cells developed glomerulonephritis or lymphoproliferative disorders, respectively.

Conclusions:

• Fine-tuning of the ERK/MAPK pathway by MEK1 and MEK2 is critical for regulating B and T cell activation and function.
• Each MEK isoform plays distinct roles in lymphocyte activation and the development of autoimmune diseases.
• These findings highlight MEK1 and MEK2 as significant therapeutic targets for immune-related disorders.